GLP-1 Medicines and Mental Health Changes

NCT07368855 · Completed

Last updated 2026-05-28

This clinical trial is testing how GLP-1 medicines affect mental health in adults with obesity and depression.

Status Completed The study has finished.

Phase Not applicable Not a phased drug trial (e.g. a device or behavioral study).

Type Interventional (clinical trial)

Design open-label (no blinding) treatment study

Participants 90 people

Who can join all sexes

Timeline Started 2024-05 · est. completion 2025-07

Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT07368855 ↗

Description as written by the study sponsor.

Key question: Is the use of GLP-1 weight loss medicines - semaglutide and tirzepatide - associated with improvements in mental health and health-related quality of life? Key finding: Across six- months of GLP-1 treatment, participants reported statistically significant improvements in mental health, eating disorder symptoms, and health-related quality of life domains such as pain interference and sleep quality. Message for readers: Although GLP-1 medicines are prescribed primarily for weight loss and metabolic health benefits, growing evidence suggests that these medicines may also facilitate meaningful improvements in mental health and quality of life.

Treatments tested

GLP-1 Drug

Wegovy or Zepbound

Main thing measured	Beck Depression Inventory-2
Sponsor	University of California, San Diego
Conditions studied	Obesity, Depression, GLP-1
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07368855 ↗